" /> Tremelimumab - CISMeF





Preferred Label : Tremelimumab;

NCIt synonyms : Anti-CTLA4 Human Monoclonal Antibody CP-675,206; Anti-CTLA4 Human Monoclonal Antibody CP-675 206; Immunoglobulin G2, Anti-(Human CTLA-4 (Antigen)) (Human Monoclonal CP-675206 Clone 11.2.1 Heavy Chain) Disulfide with Human Monoclonal CP-675206 Clone 11.2.1 Light Chain, Dimer; Tremelimumab-actl;

NCIt related terms : ticilimumab;

NCIt definition : A human IgG2 monoclonal antibody directed against the T-cell receptor protein cytotoxic T-lymphocyte-associated protein 4 (CTLA4). Tremelimumab binds to CTLA4 and blocks the binding of the antigen-presenting cell ligands B7-1 and B7-2 to CTLA4, resulting in inhibition of B7-CTLA4-mediated downregulation of T-cell activation; subsequently, B7-1 or B7-2 may interact with another T-cell surface receptor protein, CD28, resulting in a B7-CD28-mediated T-cell activation unopposed by B7-CTLA4-mediated inhibition.;

Alternative definition : NCI-GLOSS: A monoclonal antibody being studied in the treatment of melanoma and some other types of cancer. Ticilimumab is made in the laboratory and binds to a protein called CTLA-4 on T cells (a type of white blood cell). CTLA-4 is involved in preventing the activation of T-cells. Ticilimumab may block CTLA-4 and help the immune system kill cancer cells. It is a type of immunomodulatory agent.;

UNII : QEN1X95CIX;

CAS number : 745013-59-6;

Drug name : Imjudo;

Molecule name : CP-675; CP-675,206; CP-675206; CP 675206; CP 675;

Codes from synonyms : CDR0000559131; 514;

Details


Keyword's position in hierarchy(ies) : arborescence

You can consult :


Nous contacter.
08/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.